← Leaderboards
Richard A Cone
Johns Hopkins University
$17,702,134
Attributed
$19,652,142
Total exposure
21
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$23,048,338 · 22
By mechanism
R44$10,171,925 · 6
P01$3,396,196 · 1
U01$2,013,569 · 1
R43$1,997,147 · 8
R01$1,621,243 · 1
U19$1,569,484 · 2
Top collaborators
- Justin S. Hanes12 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- David D. Celentano$57,488,358
- James E.k Hildreth$35,159,425
- Ying-Ying Wang$101,404
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPathogenMucous Body SubstanceSurfaceBaseDoseVaginaSafetyInfectionIn VitroMonoclonal AntibodiesDesignPreventMicrobicideVirusImmunoglobulin GSimplexvirusPredispositionMucous MembraneMucinsAntiviral AgentsIn VivoToxic EffectWoman
Grant awards (53)
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV$1,037,049
R44 · FY2024 · AI · contact PI
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV$1,036,484
R44 · FY2023 · AI · contact PI
INDâenabling development of MMâ008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring$1,028,445
R44 · FY2023 · HD · contact PI
INDâenabling development of MMâ008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring$1,039,122
R44 · FY2022 · HD · contact PI
Development of RespiraClear for targeted mucosal treatment of RSV infections$891,585
R44 · FY2022 · AI · contact PI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV$995,652
R44 · FY2021 · AI · contact PI
In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring$756,985
R44 · FY2021 · HD · contact PI
Development of RespiraClear for targeted mucosal treatment of RSV infections$658,372
R44 · FY2021 · AI · contact PI
Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks$306,500
R43 · FY2021 · AI · contact PI
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV$306,500
R44 · FY2021 · AI · contact PI
Multipurpose vaginal ring for non-hormonal contraception and preventing bacterial vaginosis$265,970
R43 · FY2021 · HD · contact PI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV$999,032
R44 · FY2020 · AI · contact PI
In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring$972,804
R44 · FY2020 · HD · contact PI
Inhaled 'muco-trapping' antibody as universal immunotherapy for influenza virus infections$275,437
R43 · FY2020 · AI · contact PI
Aerosol immunotherapy for treatment of human metapneumovirus infection$261,742
R43 · FY2020 · AI · contact PI
Development of RespiraClear for targeted mucosal treatment of RSV infections$224,961
R44 · FY2019 · AI · contact PI
Non-hormonal contraception based on vaginal delivery of multimeric sperm-binding antibodies$224,728
R43 · FY2019 · HD · contact PI
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV$224,934
R44 · FY2018 · HD · contact PI
Nebulized 'muco-trapping' antibodies for treating respiratory syncytial virus (RSV) infections$224,893
R43 · FY2018 · AI · contact PI
Sustained vaginal delivery of monoclonal antibodies for preventing HIV transmission$224,883
R43 · FY2018 · AI · contact PI
Development of a biologic for non-hormonal contraception$212,994
R43 · FY2018 · HD · contact PI
Mucus Penetrating Particles for Rectal Microbicides$464,117
R33 · FY2015 · AI
Optimizing Plantibodies for Trapping HIV and HSV in Cervovaginal Mucus$108,020
U19 · FY2015 · AI · contact PI
Mucus Penetrating Particles for Rectal Microbicides$472,556
R33 · FY2014 · AI
Pathogen trapping by genital mucus secretions$317,540
R01 · FY2014 · HD
Optimizing Plantibodies for Trapping HIV and HSV in Cervovaginal Mucus$144,069
U19 · FY2014 · AI · contact PI
Mucus Penetrating Particles for Rectal Microbicides$451,874
R33 · FY2013 · AI
Pathogen trapping by genital mucus secretions$310,027
R01 · FY2013 · HD
Optimizing Plantibodies for Trapping HIV and HSV in Cervovaginal Mucus$153,696
U19 · FY2013 · AI · contact PI
Pathogen trapping by genital mucus secretions$326,688
R01 · FY2012 · HD
Mucus Penetrating Particles for Rectal Microbicides$240,689
R21 · FY2012 · AI
Optimizing Plantibodies for Trapping HIV and HSV in Cervovaginal Mucus$160,062
U19 · FY2012 · AI · contact PI
Pathogen trapping by genital mucus secretions$326,688
R01 · FY2011 · HD
Mucus Penetrating Particles for Rectal Microbicides$199,793
R21 · FY2011 · AI
Pathogen trapping by genital mucus secretions$340,300
R01 · FY2010 · HD
Mucus-penetrating nanoparticles for sustained microbicide delivery$244,745
R21 · FY2009 · AI
Duet cervical barrier device for maximizing protective efficacy of microbicides$216,153
U01 · FY2009 · AI · contact PI
Duet cervical barrier device for maximizing protective efficacy of microbicides$262,235
U01 · FY2008 · AI · contact PI
Mucus-penetrating nanoparticles for sustained microbicide delivery$205,000
R21 · FY2008 · AI
Core--Tests for microbicide efficacy and safety$165,476
U19 · FY2008 · AI · contact PI
Duet cervical barrier device for maximizing protective efficacy of microbicides$428,625
U01 · FY2007 · AI · contact PI
Core--Tests for microbicide efficacy and safety$412,556
U19 · FY2007 · AI · contact PI
'Duet' cervical barrier device for maximizing protectiv*$551,860
U01 · FY2006 · AI · contact PI
Core--Tests for microbicide efficacy and safety$133,012
U19 · FY2006 · AI · contact PI
Duet cervical barrier device for maximizing microbicides$554,696
U01 · FY2005 · AI
Core--Tests for microbicide efficacy and safety$140,929
U19 · FY2005 · AI
Core--Tests for microbicide efficacy and safety$151,664
U19 · FY2004 · AI
BLOCKING INFECTIOUS ENTRY OF STD PATHOGENS$870,914
P01 · FY2003 · AI
BLOCKING INFECTIOUS ENTRY OF STD PATHOGENS$825,438
P01 · FY2002 · AI
BLOCKING INFECTIOUS ENTRY OF STD PATHOGENS$7,562
P01 · FY2002 · AI
BLOCKING INFECTIOUS ENTRY OF STD PATHOGENS$824,199
P01 · FY2001 · AI
BLOCKING INFECTIOUS ENTRY OF STD PATHOGENS$844,875
P01 · FY2000 · AI
BLOCKING INFECTIOUS ENTRY OF STD PATHOGENS$23,208
P01 · FY2000 · AI